This article is more than 5 years old. Information may no longer be current.
Macula Risk testing still available to Medicare patients
Click Here to Manage Email Alerts
ArcticDx released a statement clarifying that its Macula Risk PGx test, which provides a risk assessment for age-related macular degeneration, remains available to Medicare patients despite reimbursement issues.
ArcticDx President and CEO Greg Hines told Primary Care Optometry News he is hopeful that Medicare testing reimbursement will be restored.
In the meantime, Macula Risk PGx is still an option for Medicare patients, and they will have no out-of-pocket fees associated with the test, he said.
"Arctic continues to provide Macula Risk testing services for your Medicare patients," Hines said. "The company does not require Advance Beneficiary Notice forms from patients and we do not intend to bill Medicare patients for these testing services.
"Over the past 4 years Arctic has been providing Macula Risk as a Medicare insured service,” he said. “Unfortunately, Medicare reimbursement for molecular diagnostic testing services (including Macula Risk) has been interrupted, but we continue to negotiate for the payment of these claims. Please be advised that Arctic will continue to accept Medicare testing requests as usual.
"We remain optimistic that reimbursement will be reinstated," Hines concluded.